1cP-AL-LAD

{{Short description|Chemical compound}}

{{cs1 config |name-list-style=vanc |display-authors=6}}

{{Drugbox

| IUPAC_name = (6aR,9R)-4-(cyclopropanecarbonyl)-N,N-diethyl-7-prop-2-enyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide

| image = 1CP-AL-LAD_structure.png

| width = 200

| tradename =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_US_comment =

| routes_of_administration =

| CAS_number =

| PubChem = 162368406

| ChemSpiderID =

| UNII = HH7F72QLZ3

| C=26 | H=31 | N=3 | O=2

| smiles = CCN(CC)C(=O)[C@@H]1C=C2[C@@H](Cc3cn(C(=O)C4CC4)c4cccc2c34)N(C1)CC=C

| StdInChI = 1S/C26H31N3O2/c1-4-12-28-15-19(25(30)27(5-2)6-3)13-21-20-8-7-9-22-24(20)18(14-23(21)28)16-29(22)26(31)17-10-11-17/h4,7-9,13,16-17,19,23H,1,5-6,10-12,14-15H2,2-3H3/t19-,23-/m1/s1

| StdInChIKey = VSABTUDYQCMWKE-AUSIDOKSSA-N

}}

1cP-AL-LAD is an analog of lysergic acid diethylamide (LSD) which has psychedelic effects and is thought to act as a prodrug for AL-LAD. It has been sold as a designer drug, first identified in France in June 2021.{{Cite journal | vauthors = Morais J, Evans-Brown M, Gallegos A, Christie R, Jorge R, Planchuelo G, Sedefov R |date=2022-09-01 |title=New psychoactive substances: 25 years of early warning and response in Europe. An update from the EU Early Warning System |url=https://www.sciencedirect.com/science/article/pii/S2352007822000944 |journal=Toxicologie Analytique et Clinique |series=30th meeting of SFTA- 59th meeting of TIAFT - September 2022 |volume=34 |issue=3, Supplement |pages=S29–S30 |doi=10.1016/j.toxac.2022.06.022 |bibcode=2022ToxAC..34S..29M |issn=2352-0078|url-access=subscription }}